header logo image


Page 735«..1020..734735736737..740750..»

Global Animal Stem Cell Therapy Market Trends, Size, Analysis and Forecast from 2020 to 2025 – Fusion Science Academy

January 23rd, 2020 11:44 pm

The research dives deep into the global share, size, and trends, as well as growth rate of the Animal Stem Cell Therapy market to project its progress during the forecast period, i.e., 20202025. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Animal Stem Cell Therapy market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, demand and production capability across different countries.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Animal Stem Cell Therapy market.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.reportsweb.com/inquiry&RW00013146465/sample

Researchers conducting the research also carry out a comprehensive analysis of the recent amendments in the government regulation and their impact on the competitive landscape of the industry. The research assesses the recent progress in the competitive landscape including collaborations, joint ventures, product launches, acquisitions, and mergers, as well as investments in the sector for research and development.

The report profiles the key players in the industry along with a detailed analysis of their individual positions against the global landscape. The researcher provides an extensive analysis of the Animal Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

The major manufacturers covered in this report:

Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel, etc.

Scope of the report:

This research evaluates micro-markets and takes a closer look at the different growth trends, future prospects and regulations that will regulate the industry in the coming years. Researchers have also included a few top performers in the sector to calculate their industry shares and core competencies. The research explains technological developments in the sector along with upcoming areas of the industry that might potentially attract massive investments.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.reportsweb.com/inquiry&RW00013146465/discount

Most important Products of Animal Stem Cell Therapy covered in this report are:

Most important Application of Animal Stem Cell Therapy covered in this report are:

Scope of the study:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsweb.com/inquiry&RW00013146465/buying

About ReportsWeb:

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the world. We help our clients in their decision support system by assisting them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Name: Sameer JoshiEmail: [emailprotected]Phone: +1-646-491-9876

Here is the original post:
Global Animal Stem Cell Therapy Market Trends, Size, Analysis and Forecast from 2020 to 2025 - Fusion Science Academy

Read More...

Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 – Fusion Science Academy

January 23rd, 2020 11:44 pm

Global High Pressure Balloon Catheter Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global High Pressure Balloon Catheter industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2582408&source=atm

For competitor segment, the report includes global key players of High Pressure Balloon Catheter as well as some small players.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of High Pressure Balloon Catheter in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market includeBoston ScientificMedtronicTeleflexAbbott VascularCook MedicalOlympusBDTerumoB. BraunOptimedColoplastSIS-MedicalNordson MedicalOsypka MedicalKossel Medtech (Suzhou) Co., LtdBy the product type, the market is primarily split intoPolyurethaneNylonOthers

By the end users/application, this report covers the following segmentsHospitalsClinicsOthers

We can also provide the customized separate regional or country-level reports, for the following regions:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaAustraliaIndonesiaThailandMalaysiaPhilippinesVietnamEuropeGermanyFranceUKItalyRussiaCentral & South AmericaBrazilMiddle East & AfricaTurkeyGCC CountriesEgyptSouth Africa

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2582408&source=atm

Important Key questions answered in High Pressure Balloon Catheter market report:

What will the market growth rate, Overview, and Analysis by Type of High Pressure Balloon Catheter in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in High Pressure Balloon Catheter market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of High Pressure Balloon Catheter market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2582408&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe High Pressure Balloon Catheter product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of High Pressure Balloon Catheter , with price, sales, revenue and global market share of High Pressure Balloon Catheter in 2019 and 2015.

Chapter 3, the High Pressure Balloon Catheter competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the High Pressure Balloon Catheter breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, High Pressure Balloon Catheter market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe High Pressure Balloon Catheter sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to read the rest:
Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy

Read More...

Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 – Fusion Science Academy

January 23rd, 2020 11:44 pm

In 2019, the Stem Cell Therapy market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Stem Cell Therapy market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Stem Cell Therapy market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Stem Cell Therapy market research study, 2018 is considered as the base year, and 2019-2019 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Global Stem Cell Therapy market report on the basis of market players

The report examines each Stem Cell Therapy market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Stem Cell Therapy market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Report available at a discounted price exclusively!!! Offer ends today!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market report answers the following queries:

The Stem Cell Therapy market report provides the below-mentioned information:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Research Methodology of Stem Cell Therapy Market Report

The global Stem Cell Therapy market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Stem Cell Therapy market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Stem Cell Therapy market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read more:
Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 - Fusion Science Academy

Read More...

Genome Medical Adds Population Genomics Offering to Enable Increased Access for Individuals Nationwide – P&T Community

January 23rd, 2020 11:43 pm

SOUTH SAN FRANCISCO, Jan. 23, 2020 /PRNewswire/ --Genome Medical, a leader in telegenomics-based clinical care, today announced that it has expanded its services to enable collaborative population genomics programs with health systems across the country. To support this augmented offering, the company has appointed renowned geneticist Huntington Willard, Ph.D., as Chief Scientific Officer and SVP, Medical Affairs.

Genome Medical uses its Genome Care DeliveryTM platform to drive large scale population genomics programs that will increase the understanding of genetic factors within specific populations. The information gleaned from these programs has the potential to help health systems and their clinicians understand how genetics and genomics contribute to the overall health and well-being of patients within the communities they serve.

The comprehensive range of services offered to health systems includes strategic advice and guidance; program development and implementation support; engagement of patients and providers; genetic testing coordination; and return of results to both patients and providers. Health systems will be able to create programs supported by a national network of licensed medical geneticists and genetic counselors, who are accessible on-demand through the company's telemedicine platform. This benefits not only patients and their families, but also clinicians who can receive consultation to determine appropriate clinical action plans.

"I am thrilled to bring new talent to the Genome Medical team as we expand our services," said Lisa Alderson, co-founder and CEO of Genome Medical. "Hunt has led multiple significant initiatives in genomics, including launching the National Precision Health program at Geisinger. Under his leadership, this team will help us execute on key partnerships with hospitals and health systems to further democratize genomics for all populations."

Willard brings decades of leadership experience in genetics and genomics to his position at Genome Medical, where he will oversee various strategic initiatives including clinical and research partnerships in population genomics with hospitals and health systems. He is an elected member of the National Academies of Medicine and of Sciences, a former president of the American Society of Human Genetics, and founding director of the Duke Institute for Genome Sciences and Policy. Most recently, he served as founding director of Geisinger National Precision Health.

"Genome Medical's business needs as a leading medical practice and telegenomics company align well with my expertise in developing and operating precision health initiatives," Willard said. "I look forward to working with Lisa and the team to transform the way hospitals and health systems utilize population genomics programs to improve the quality of clinical care."

In addition to Willard, Genome Medical also announced expansion of its population genomics team by welcoming two other former team members from Geisinger National, one of the world leaders in population genomics and precision health:

Genome Medical's network of genetic specialists and cloud-based Genome Care Delivery technology platform overcome the service delivery challenges in genetics. More than 50 clinicians are available for on-demand, virtual care in all 50 states across six specialty areas; this level of reach is paramount to the successful implementation of population genomics. The platform delivers education, engagement and provider-to-provider e-consultations, as well as genetic wellness assessments and screening for population health management.

About Genome MedicalGenome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care. Through our nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. We also help healthcare providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. We are shepherding in a new era of genomic medicine by creating easy, efficient access to top genetic experts. Genome Medical is headquartered in South San Francisco. To learn more, visit http://www.genomemedical.comand follow @GenomeMed.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genome-medical-adds-population-genomics-offering-to-enable-increased-access-for-individuals-nationwide-300991681.html

SOURCE Genome Medical

Here is the original post:
Genome Medical Adds Population Genomics Offering to Enable Increased Access for Individuals Nationwide - P&T Community

Read More...

Whats wrong with my son? Wisconsin rejects $4 test for rare, terminal disease – WITI FOX 6 Milwaukee

January 23rd, 2020 11:43 pm

Please enable Javascript to watch this video

WISCONSIN RAPIDS They thought their newborn baby was perfect, but a Wisconsin couple soon discovered he had a deadly disease. The FOX6 Investigators found the state of Wisconsin has, so far, declined to test newborns for the rare condition that killed their son.

It's a genetic disorder known as Krabbe disease, which affects fewer than 1 in 100,000 children. Experts say early detection is critical to an affected child's chances of survival. Other states are adding newborn screening for Krabbe, but state officials in Wisconsin say there's not enough research to justify the four-dollar test.

The first day of parenthood is all about nerves, and relief.

"What do I do?!" Kevin Cushman recalls thinking, the day his son, Collin, was born. "'I don't know what to do!' I said, 'Is he OK?' And she said, 'He's perfect.'"

"And he was," said Judy Cushman, Collin's mom. "I mean, he was perfect when he was born. He was perfect."

Kevin always wanted a boy, but he and Judy agreed that's not what mattered most.

"Just as long as they're healthy," he said.

"As long as the child is healthy," Judy repeated. "And I had every reason to believe that my child was going to be healthy."

Ten years later, they can hardly remember thosefirst few months when Collin was just like any other baby.

What they will never forget is when everything changed.

"His whole body is stiff," Kevin says in a home video recorded when Collin was about 9 months old.

That's when Collin's muscles began to get tight. His reactions slowed. He became incessantly irritable. And, eventually, his face fell into an open-mouthed expression that would never go away.

"I remember holding Collin with tears, going, 'What's wrong with my son?'" Kevin said.

The answer was worse than they'd ever imagined. Collin had a rare, genetic disorder known as Krabbe disease. That meant he was going to die at an early age.

"You know, your dreams are shattered," Kevin said.

First, there would be years of tube feedings, vibration machines, and round-the-clock care.

"It was... challenging," Kevin said.

Collin was lucky enough to survive until the age of 9. Most Krabbe children die before they turn 2.

"It's horrifying," said Dr. Barbara Burton, a specialist in genetic medicine at Lurie Children's Hospital of Chicago.

She says Krabbe disease is a form of leukodystrophy that causes the body's nerves to degenerate.

"You lose the coating on the nerve fibers that transmit signals from one nerve cell to another," said Dr. Burton.

"So as the myelin was destroyed, [Collin] slowly lost more and more abilities," his father said.

The disease affects fewer than one in every 100,000 newborns -- perhaps even as few as one in 400,000 -- and there is no cure. There is, however, a way to treat the disease and improve a child's chance of living a longer, more functional life.

"We would've had a totally different boy," Judy said.

The trouble is, the treatment -- a hematopoietic stem cell transplant, or HSCT -- only works to treat Krabbe if it's done within a baby's first 30 days alive. Most parents have no idea their child even has the disease until symptoms surface months later.

"By the time the symptoms show themselves, it's too late," Kevin said. "There's no hope."

In 2018, Dr. Burton joined a team of experts in publishing guidelines that recommend newborns be screened for Krabbe before they leave the hospital. All 50 states already have programs to test newborns for a host of other disorders by pricking the child's heel to draw blood and placing that blood inside circles on a laboratory test card.

"It might just be another circle that they fill out," Kevin Cushman said.

New York was the first state to start testing for Krabbe in 2006, followed by Missouri, Kentucky, Ohio, Tennessee, and Illinois. At least five more states are now working to implement the screening, but so far, Wisconsin has rejected efforts to add Krabbe to the 48 disorders tested for at birth, in part, because there's not enough long-term research to prove the treatment works.

"I hear that argument over and over again, and I think it's ridiculous because the same thing could be said for almost any other condition for which we do newborn screening," said Dr. Burton.

Five years ago, the Cushmans nominated Krabbe disease for inclusion in Wisconsin's newborn screening program, but Chuck Warzecha, deputy administrator for the Wisconsin Division of Public Health, said the test results in too many "false positives."

"There are some risks and emotional impacts on the family when they get that false positive," said Warzecha.

The state's 2015 review of Krabbe testing relied on research that's now more than 10 years old and Dr. Burton says newer testing is more accurate.

"Our technology has gotten much better," said Dr. Burton.

In addition, some Krabbe patients who have gotten transplants are living longer more functional lives.

"We know if it gets detected early that it's treatable," said Senator Patrick Testin, a Stevens Point Republican. He's working on a bill to require Krabbe testing in Wisconsin -- as long as the cost doesn't derail his plan.

"Yeah, that might be a potential roadblock," Testin said.

In 2015, the state said Krabbe screening would cost an extra $300,000 a year, or roughly $4 per test.

"For $4, why wouldn't you?" Judy asked.

"Try to imagine yourself in the shoes of a family who finds out their child has Krabbe disease, and then talk about whether $4 per baby is worth it," Dr. Burton said.

"No child should have to go through this," Kevin said.

Even if Collin had been tested for Krabbe at birth, the Cushmans can't say for sure if they would have gone through with a transplant. The procedure is risky, and some children don't survive.

"I would've given anything to have had that choice," Kevin said. "Even if it didn't change the outcome. As a father, I think I would've felt at least a little more comfortable knowing that I literally did everything I could to save my child."

Of course, the risk of an early death without the transplant is 100%.

On Jan. 6, 2019 -- seven years to the day after Collin was diagnosed -- his father held him for the last time.

"I was gonna hold him as long as it took," he said. "If it took two days before he passed, I was not gonna let go of him."

It's not how the Cushmans imagined things when they welcomed their firstborn child into the world, but they couldn't have asked for a better goodbye.

"Surrounded by family," said Kevin Cushman. "It was perfect."

Krabbe is not on the federal government's recommended list of disorders for newborn screening, but two similar disorders are, including Pompe disease. The state of Wisconsin recently completed a pilot project for Pompe, and they are considering whether to test for it permanently. If they do, DHS says adding Krabbe testing after that would be less expensive than it would have been in the past, because the equipment and training would be similar.

For now, Krabbe is not part of Wisconsin's newborn screening program. The Cushmans intend to keep pushing until it is.

Krabbe is a recessive genetic disorder that is passed down, like blue eyes or attached earlobes. A child is only at risk if both parents are carriers of the mutated gene that causes Krabbe. Even then, there's only a 25% chance the child will get the Krabbe gene from both of them.

Parents can be tested before having a baby to determine if they are carriers of the disease, but -- because it is so rare -- most soon-to-be parents know nothing about it.

Even after Collin was diagnosed, the Cushmans chose to have a second child. This time, they knew there was a 25% risk the second child would have Krabbe. Judy Cushman called it "the worst lottery ever."

Fortunately for them, Kendra Cushman was born without the disease. Five years later, she is symptom free.

43.038902-87.906474

Here is the original post:
Whats wrong with my son? Wisconsin rejects $4 test for rare, terminal disease - WITI FOX 6 Milwaukee

Read More...

Autistic people have increased incidence of neurological problems – Spectrum

January 23rd, 2020 11:43 pm

Brain food: Autism appears to be closely linked to headaches.

Maya23K / iStock

People with autism have more brain-related health problems, such as headaches and epilepsy, than typical people do, according to a survey of twins1. The study is the first to look at associations between autism and physical health problems among twins.

The study found no association between autism and other physical conditions, such as gastrointestinal problems and infectious diseases, however.

I find it particularly remarkable that our results are so clear in terms of confirming that [autism] but also autistic traits are associated with neurological alterations, and no other somatic issues are equally associated, says lead investigator Sven Blte, director of the Center of Neurodevelopmental Disorders at the Karolinska Institutet in Stockholm, Sweden. The findings also support the idea that autism is a condition of the brain, Blte says, and not of the immune system or the gut.

Understanding associations such as these can help clinicians look out for autistic peoples health problems. That is particularly important when treating people who may have difficulties communicating, says Thomas Challman, medical director of the Geisinger Autism and Developmental Medicine Institute in Lewisburg, Pennsylvania.

Associated health issues can be really important in maximizing peoples quality of life, Challman says. If there is a higher rate of various other medical conditions in individuals with a developmental condition, we want to have a higher level of alertness in detecting these things.

The researchers surveyed 172 pairs of twins both identical and fraternal enrolled in the Roots of Autism and ADHD Twin Study Sweden. Of this group, 75 pairs have at least one twin with autism; 18 pairs of identical twins have only one twin with autism. Because identical twins who grow up together share a nearly identical genetic background and environment, they are particularly helpful in teasing out how these factors can shape an individuals health.

The researchers gave the participants, who ranged in age from 8 to 31 years, diagnostic exams and the Social Responsiveness Scale, Second Edition, a standard survey of autism traits. The participants or their parents then filled out a questionnaire that asked about the participants history of infectious and cardiovascular diseases, neurological problems such as epilepsy and headaches, gastrointestinal problems such as lactose intolerance, and immunological conditions such as asthma and allergies.

The researchers found that people with an autism diagnosis have more neurological and immunological health problems than those without the diagnosis. They also found that within identical twin pairs in which only one twin has autism, the twin with more neurological problems is more likely to be autistic than the neurotypical twin is.

In their analysis, the researchers weighted common problems such as headaches as equal to rarer problems such as heart defects. This approach may have affected the results, so the team should confirm the finding in a larger sample size, says Lior Brimberg, who was not involved in the research. Brimberg is assistant professor of neuroimmunology at the Feinstein Institute for Medical Research in Manhasset, New York.

The researchers also did not control for age or gender.

The fact that the study did not find an association between autism and gastrointestinal problems is surprising, notes Barbara McElhanon, assistant professor of pediatric gastroenterology at Emory University in Atlanta, Georgia, and a clinician at Childrens Healthcare of Atlanta.

The study may have missed this association because gastrointestinal problems, such as constipation, tend to be transient, she says, and may be more easily forgotten when responding to questionnaires than are persistent conditions such as epilepsy. Only 1.2 percent of the participants with autism and 0.8 percent of those without autism reported experiencing constipation both at the low end of prevalence estimates in the general public, which range from 0.7 to nearly 30 percent.

The study is also important in evaluating how much of autism and its traits are heritable versus environmental, Brimberg says.

Because identical twins share nearly all of their DNA, the association between autism and neurological problems in identical twins suggests that something beyond genetics, such as an interaction between genes and the environment, is at play in the origin of both conditions, Brimberg says.

Theyre almost sharing the same environment, theyre almost sharing the same genetics, and you still dont see 100 percent penetration of [autism], Brimberg says.

Brimberg notes that a study in July concluded that autism is 80 percent heritable2. I think this study suggests that, you know, not necessarily, she says.

The researchers hope to analyze a larger database, such as the Child and Adolescent Twin Study in Sweden, which has more than 32,000 participants. Ultimately, they say, they hope their work will help scientists identify autism subtypes and pathways that underlie the condition.

Go here to see the original:
Autistic people have increased incidence of neurological problems - Spectrum

Read More...

Myriad Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer – GlobeNewswire

January 23rd, 2020 11:43 pm

SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSKs PARP inhibitor Zejula (niraparib). Myriads filing is based on the positive results from the Phase 3 PRIMA trial of Zejula that was published online in the New England Journal of Medicine in September 2019.

The myChoice CDx test provides valuable molecular insights into tumors and helps identify women with ovarian cancer who are most likely to benefit from PARP inhibitors, said Nicole Lambert, president, Myriad Oncology. This regulatory submission represents another important step forward for precision medicine and ensuring that women have access to the most advanced therapies.

Myriad's myChoice CDx is the most comprehensive homologous recombination deficiency test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice CDx test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).

About Ovarian CancerOvarian cancer affects approximately 22,000 women per year in the United States according to the American Cancer Society. Typically, ovarian cancer is diagnosed at later stages when it has metastasised to other areas of the body and only 20 percent of patients are diagnosed with early stage disease. Ovarian cancer is one of the deadliest cancers with approximately 14,000 deaths per year attributed to the disease. Patients with certain characteristics such as a family history of the disease, certain genetic mutations such as those in the BRCA1 and BRCA2 genes, obesity and endometriosis face a higher risk from ovarian cancer.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

GSK is commercializing ZEJULA. ZEJULA is a registered trademark of GSK.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to women getting access to the most advanced therapies; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Excerpt from:
Myriad Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer - GlobeNewswire

Read More...

St. Catherine Hospital Scientists on Pharmacogenomics and Artificial Intelligence – Total Croatia News

January 23rd, 2020 11:43 pm

January 23, 2020 - A Croatian group of scientists from the St. Catherine Special Hospital participated in the publication of yet another remarkable scientific paper, this time explaining the concept of pharmacogenomics testing based on the principles of artificial intelligence.

"Pharmacogenomics" is one of the world's leading scientific publications in the field of pharmacogenomics (PGx) and their latest issue included an article titled "Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data".

The authors are a group of the Croatian and American scientists, led by Professor Dragan Primorac, who propose the model of the systematic introduction of PGx testing into clinical practice. Along with that, they propose the implementation of the concept into the health systems of various countries, using Artificial Intelligence (AI) models, as well as some sub-systems within the AI framework, such as so-called Machine Learning.

Through the specific algorithms analysing the data, the patients' data is compared with all the data already deposited in large databases (using the Big Data approach), with the goal of optimising diagnostic procedures, the prevention of disease on time, and personalised treatment. Unlike the typical model of machine learning where the algorithms are defined by certain parameters based on expert knowledge, the concept of AI primarily uses the neural networks, continually evaluating a large amount of data and processing it in a similar manner to human thinking.

Pharmacogenomics analyses a whole series of genes, or even the entire genome, and then studies the connections between the genetic predisposition of an individual and their reaction to a drug. It helps understand why some people respond to some medicines while others don't, why some people need to have the doses of their medicines adjusted to get the perfect therapeutic response, and it can even warn you if a patient won't respond to therapy at all or even when someone will experience toxic side effects.

The model proposed in the paper is based on the experiences by the St. Catherine Hospital and the PGx testing it has been performing in cooperation with OneOme American company (a spin-off company of the famous Minnesotan Mayo Clinic).

The testing uses the RightMed system and analyses 25 genes at the same time (CYP1A2, CYP2B6, CYP2C9, CYP2C19, the CYP2C cluster, CYP2D6, CYP3A4, CYP3A5, CYP4F2, COMT, DPYD, DRD2, GRIK4, HLA-A, HLA-B, HTR2A, HTR2C, IFNL4, NUDT15, OPRM1, SLC6A4, SLCO1B1, TPMT, UGT1A1, VKORC1), which are responsible for the synthesis of the enzymes important for the drug's metabolism (especially the genes of the enzymatic system of cytochrome P450), transport proteins, receptors, other proteins important for the functioning of drugs, as well as those from the HLA system, which is important for the reactions of oversensitivity to medicines.

The system allows for the prediction of the response of each patient for over 300 of the most frequently used medicines, and so the patients are given the possibility to find the one which will help them best. All of the algorithms used in the system related to the use of the genetic information and the selection of the drug and its dosage are following the Clinical Pharmacogenetics Implementation Consortium(CPIC) guidelines.

The algorithm of the analysis of genes responsible for the drug metabolism of each patient will sort them into five categories of metabolizers: slow, intermediary, normal, fast or very fast. The paper also includes a very detailed SWOT (Strength, Weakness, Opportunity, Threat) analysis of the proposed strategy, which can lead to a significant new step in the development of modern medical sciences.

The importance of the introduction of PGx methods into routine clinical practice is best confirmed by the information recently published in the leading American medical sciences journal, JAMA, in which it was said that in the US, more than 2 million hospitalized patients have serious side-effects from the drugs they were given annually, and over 100.000 of them die. Some estimate that the number is even higher today. Today, side-effects from drugs constitute the fourth cause of mortality in all populations. In the US, the health system spends 136 billion dollars a year to mitigate the damage done by the side-effects of drugs. European data shows that between 7 and 13 percent of patients get admitted into hospitals because of the side-effects of drugs, and 30 to 50 percent of patients do not respond to therapy at all.

Professor Dragan Primorac said that the "right therapy for the right patient at the right time" is the key phrase of personalized medicine, however that can't be achieved without an insight into the molecular status of the patient.

Our goal is to reduce the morbidity caused by the side-effects of drugs to the lowest possible level, as well as to integrate pharmacogenomics through the concept of AI with all the other diagnostic procedures into an integrated system which will lead to the optimisation of diagnostic and therapeutical procedures.

The proposed concept of the integration of PGx methods into clinical practice, developed by the scientists from the St. Catherine Special Hospital and the OneOme company, has attracted huge interest on the world's health market, and the first implementation of the model outside of Croatia is soon to start in German health institutions.

More here:
St. Catherine Hospital Scientists on Pharmacogenomics and Artificial Intelligence - Total Croatia News

Read More...

Science Talk – What’s coming for cancer in the 2020s – The Institute of Cancer Research

January 23rd, 2020 11:43 pm

Image: The ICR's Dr Valeria Cazzaniga in the lab

With the turn of a new decade many people are looking at the best things that came out of the last 10 years, from films, music and gadgets to the most innovative medical advances. But amongst all the retrospection, others are choosing to look ahead.

Recently, I attended the launch of a new reportpublished by University College London(UCL) aiming to set the agenda for cancer research and care in the 2020s. The report argues that over the next few years, our ability to better control cancer will not be the result of one or two major breakthroughs, but the accumulation of incremental advances in many different areas.

One reference I loved from the report was how the worldwide pursuit of better cancer treatments is arguably the biggest scientific project in history, dwarfing even the US moon landings of the 70s, and its true I can't fit all of the really exciting things coming for cancer over the next 10 years into one blog post!

Instead, Ive picked three topics mentioned in the report that have the potential to be instrumental for better cancer control in the next decade, and what the ICR is already doing to help.

Alongside its report, UCL surveyed more than 2,000 people about their attitudes towards cancer research and treatment in 2019. Perhaps not surprisingly, given that one in two of us will be diagnosed with the disease in our lifetime, half of the British population believe that tackling cancer is their biggest public health priority.

But, will there ever be a cure for cancer? This question gets asked of our researchers often, and was addressed in a recent blog postby our CEO, Professor Paul Workman. Cancer is a disease made up of more than 200 main types, and a plethora of other molecular subtypes, so its unlikely we will ever have a single cure.

During the report launch, Professor Charles Swanton of the UCL Cancer Institute spoke of the success of the past 20 years in understanding more about the complexity, diversity and instability of cancers and how they evolve to develop drug resistance.

Cancer evolution is the cause of a vast majority of cancer deaths, and at The Institute of Cancer Research, it will be a central area of focus over the next decade.

While we share the goal of patients and the public in wanting cancer to be completely cured, focusing exclusively on curing cancer can risk overlooking some of the amazing progress that has already been made in the field with statistics showing that the average length of survival from cancer approximately doubled over a 10-year period as new targeted drugs, combination treatments and immunotherapies begin to improve long-term control.

As we begin the new decade, the ICR is launching the worlds first Darwinian drug discovery programme, within our new Centre for Cancer Drug Discovery, aimed at achieving further dramatic improvements in the proportion of patients whose disease can be controlled long term, as well as increasing the chances that patients will be cured.

We are building a new state-of-the-art drug discovery centre to develop a new generation of drugs that will make the difference to the lives of millions of people with cancer. Find out more about the Centre and about how you can help us finish it.

The Centre for Cancer Drug Discovery

At the ICR, our scientists are changing the way we think about cancer. We are combining advanced DNA sequencing and image analysis with evolutionary theory, mathematical modelling and artificial intelligence to understand and predict how cancers mutate and adapt to resist treatment.

The aim is to stay one step ahead of cancer, by creating new treatment strategies that anticipate, prevent and overcome evolution and drug resistance.

Advances in the technology to read peoples DNA have made it possible to sequence a patients whole genome or that of their tumour quickly and cheaply. That can allow researchers to predict how cancer will respond to treatment and to select the drug that is most appropriate for a patient and their tumour.

It is also increasingly possible to assess a persons risk of cancer by looking at their genetic information. These scientific advances are matched by a public appetite for genetics, which has seen enthusiastic participation in pilot studies and rather more controversially increased interest in direct-to-consumer genetic tests.

The Government have responded to increased knowledge of and interest in genetics with the imminent rollout of the NHS Genomic Medicine Service, which will embed genetic testing into primary care for the first time in the UK. The service will allow healthcare professionals to personalise treatments and interventions more than ever before.

The data gathered from this extensive testing will also be available for research once it has been anonymised so scientists can better understand cancer and its evolution. Its safe to say the Genomic Medicine Service is promising big things, and the NHS aims to embed genetic testing into routine healthcare by 2025 so watch this space!

One innovative way researchers at the ICR are using genetics to tailor cancer treatment is by looking at circulating tumour DNA DNA that has shed from tumours and circulates in the blood stream of a patient.

Circulating tumour DNA can be identified through a blood test, which is less painful than standard tissue biopsies and can often be a quicker and easier way to investigate tumour development in a patient and monitor treatment success. Results have been extremely promising.

One example is the plasmaMATCH clinical trial early results of which were released in December. In that study, ICR researchers looked at whether a blood test could detect traces of genetic faults that are known to drive breast cancer.

The study was so successful, scientists believe it is reliable enough to be routinely used by doctors in the clinic once it has passed regulatory approval.

As we learn more about cancers genetics and evolution, we start to understand the reasons for something that has been known for a long time that the more a cancer has progressed, the harder it is to treat. And that in turn is placing an increased emphasis on research to understand how cancer can be detected earlier or even prevented in the first place.

One way cancer can be detected earlier is by setting up dedicated screening programmes such as those that exist for breast cancer, bowel cancer and cervical cancer. The report from UCL called for enhanced screening programmes to improve early detection of lung cancer, but screening also has the potential to benefit many more cancer types in the future.

While screening programmes are estimated to save 10,000 lives a year in the UK through prevention and early diagnosis, there is also evidence that they are not reaching their full potential.

People live busy lives, and uptake of screening appointments is not as high as the Government would like. To address this, ministers asked Professor Sir Mike Richards, a former national cancer director, to review adult screening programmes in England.

One of the reviews key recommendations called for a new organisation to be set up that is able to manage all cancer screening under one roof. This could avoid unnecessary delays where multiple organisations are managing different aspects of the screening pathway, and might ensure accountability when things dont run smoothly.

Sir Mike also highlighted the value of targeted screening in his review. Targeted cancer screening programmes aim to identify people in the population who may have a higher risk of developing certain cancers based on factors such as genetics, lifestyle and environment. This information allows healthcare professionals to tailor screening programmes for smaller groups of people.

One example of this is with PSA testing in men which, while not proven useful in the general population, has been shown to be more effective in a smaller population of men those with a fault in their BRCA2 gene.

This research, from the IMPACT study, was conducted by researchers at the ICR. Regular screening using this test in men who have this particular gene fault could help identify those at risk of prostate cancer far sooner than current methods of diagnosis.

Targeted screening based on factors such as an individuals genetic profile will not only save the NHS money, but will avoid subjecting large numbers of people to unnecessary medical appointments.

Its an exciting time to work in the field of cancer research and treatment, and it seems pretty clear that the next 10 years are going to bring some revolutionary advances.

This blog post has highlighted just three areas where there are being dramatic advances I havent, for example, touched upon the great strides being made in areas such as precision radiotherapy, advanced imaging or AI.

Check back here in 2030, when Ill be doing a round-up of the best advances in cancer research from the last decade

Here is the original post:
Science Talk - What's coming for cancer in the 2020s - The Institute of Cancer Research

Read More...

Global CRISPR And CRISPR-Associated Genes Market Insights 2019 Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics,…

January 23rd, 2020 11:43 pm

Apex Market Research provides market research reports from more than four years. Here we have issued the research report on Global CRISPR And CRISPR-Associated Genes Market Market. The report shows the all leading market players profiles. The report represents the full market analysis of the CRISPR And CRISPR-Associated Genes market with SWOT analysis, fiscal status, present development, acquisitions, and mergers. The CRISPR And CRISPR-Associated Genes market report represents the major challenges and newer opportunities. In-depth the newer growth tactics influenced by the industry manufactures the shows the international competitive scale of this market sector. The report gives the closer views to the global vendors to understand the CRISPR And CRISPR-Associated Genes market trends and meanwhile, generate important tactical actions to boost their business. The report investigates industry growth and risk factors as well as keep updates regarding development task happening in the globe market.

Get Sample PDF for More Professional and Technical Insights at: https://www.apexmarketreports.com/Life-Science/global-crispr-and-crispr-associated-genes-market-by-451326#sample

Major Industry Player Profiles That Included by CRISPR And CRISPR-Associated Genes Market Research Report:

Thermo Fisher ScientificEditas MedicineCaribou BiosciencesCRISPR therapeuticsIntellia therapeutics, Inc.CellectisHorizon Discovery PlcSigma AldrichPrecision BiosciencesGenscriptSangamo Biosciences Inc.Lonza Group LimitedIntegrated DNA TechnologiesNew England BiolabsOrigene Technologies

Detailed view of CRISPR And CRISPR-Associated Genes Market:

For staying consistent in businesses and new initiate in the market, it is very essential to have a complete structure of the market holder. While thinking about this factor, the analysts provide a detailed view of the competitive strategies and landscape accepted by the principal players. The major feature of the market covered in this CRISPR And CRISPR-Associated Genes market report focused on opportunities, restraints, obstructions, global and regional distribution, market driving factors, and growth limiting factors.

The CRISPR And CRISPR-Associated Genes market report provides detailed data to mentor industry players while forming important business decisions. To provide this the report has used different analytical tools and procedures. In an aggressive market landscape, the report concentrate on every players detailed profile along with their product details, capacity, price, revenue, gross and contact information. CRISPR And CRISPR-Associated Genes market report consumes the production, import and export forecast by type, applications, and region with uniquely generated graph by our research team.

Market Type,

Genome EditingGenetic engineeringGRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

Market Application,

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

Customize Report And Inquiry For The CRISPR And CRISPR-Associated Genes Market Report: https://www.apexmarketreports.com/Life-Science/global-crispr-and-crispr-associated-genes-market-by-451326#inquiry

Regional Segmentation:

The report focuses on regional segmentation to assist clients to understand region-wise analysis of CRISPR And CRISPR-Associated Genes market report. The report includes the case study of the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa.

Key Objectives of This Report:

To redeem complete information to entrepreneurs about future products and technologies to be introduced in the market.To deliver access to unique information about top players of the Automotive Tyre market.The report focuses on feature about long-term and short-term strategies adopted by major players of the market along with their key developments.The report provides a country-wise analysis of the market helps to understand the market more precisely.To offer demand and growth trends of the market and segregation into segments.

Original post:
Global CRISPR And CRISPR-Associated Genes Market Insights 2019 Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics,...

Read More...

Driver eyesight and myopia awareness key concerns from national vision survey – ABC News

January 23rd, 2020 11:42 pm

Updated January 23, 2020 20:22:47

One in five middle-aged Australians are finding it difficult to read road signs while driving, according to a new survey of the nation's visual health.

The 2020 Vision Index Report survey of 1,000 people, commissioned by Optometry Australia and released today, reveals 19 per cent of respondents aged 35 to 54 admit they struggle with signs behind the wheel.

One in three people surveyed had also never heard of myopia despite a global epidemic that experts say will leave half the world myopic by 2050.

Peter van Wijngaarden, a principal investigator for the Centre for Eye Research Australia, said the findings on driver behaviour had "significant safety implications".

"The vast majority of that sort of difficulty is easily corrected with glasses or an update to existing glasses, so it's something I'd strongly encourage people, that if they are feeling that they're having trouble seeing road signs, that that's a bit of a red flag for going and seeking out an eye check," he said.

Optometrist Sophie Koh from Optometry Australia said the survey's findings backed a view that many people were "in denial" about the state of their vision, or simply avoided conditions that made it most difficult, such as driving at night.

Indeed, 22 per cent of all people surveyed indicated they squinted at night "to see better while driving", while 15 per cent of people admitted to squinting behind the wheel during the day.

Ms Koh said everyone needed regular eye tests, regardless of symptoms.

Two-thirds of parents in the survey said they had taken their children to an optometrist, yet vision experts said it was critical for all children to have their eyes tested before starting school.

"Before they start school we recommend that they get an eye exam with or without symptoms," Ms Koh said.

"A lot of children, for example, are happy with the way they see and don't know they have a vision problem because that's the way they've always seen.

"We know a lot of eye problems are undetected. But most eye diseases 75 to 90 per cent are preventable."

But they need to be caught early. Ms Koh said waiting for symptoms to arrive was leaving it too late.

Associate Professor van Wijngaarden said having children's eyes checked was particularly critical.

"Often it's hard to notice when kids aren't seeing as well as they should and we know there's a critical period in childhood where correcting vision impairment, the need for glasses for instance, is really important for development of the sense of vision," he said.

"We are actually born with quite poor vision and it's visual experience that leads to the development of our eyes and our brain together.

"Good eye checks in childhood are really important to make sure your child's going to develop the best possible vision."

Ms Koh said the rapid rise of myopia made eye testing even more critical for children.

"Ninety to 95 per cent of kids in countries like South Korea and Singapore are now myopic, and it's a direct relation to more indoor activity versus outdoor and sedentary behaviour," she said.

"The message of two hours outside play per day is most important.

"It doesn't matter if you want to read a lot and be on screens, but you need to have a protective balance, which is outdoor [time]."

Associate Professor van Wijngaarden said the myopia epidemic still was not fully understood.

"In part it's environmental risk and in part it's genetic risk," he said.

"There's certainly an evidence base building for the need for outdoor activity, some sunlight exposure and reducing your work-screen time, extended periods of close focusing work."

Australians were also ignorant of the UV-induced eye disease known as pterygium, with three-quarters of survey respondents saying they had never heard of the problem.

Yet one in 100 Australians are affected, and Queensland has the highest prevalence of the condition in the world.

The National Eye Health Survey in 2016 estimated more than 450,000 Australians had some form of vision impairment, and that figure was expected to grow rapidly with the nation's ageing population.

Topics:health-policy,occupational-health-and-safety,travel-health-and-safety,womens-health,mens-health,driver-education,education,road-transport,road,doctors-and-medical-professionals,australia,brisbane-4000,qld

First posted January 23, 2020 06:44:46

Read the original here:
Driver eyesight and myopia awareness key concerns from national vision survey - ABC News

Read More...

Early detection of Glaucoma may save your sight – Brownwood Bulletin

January 23rd, 2020 11:42 pm

January is Glaucoma Awareness Month and Brownwood Regional Medical Center along with local Ophthalmologists, Dr. Carol Boren and Dr. Larry Wood want to remind you that early detection of Glaucoma requires a comprehensive eye exam and is recommended for those ages 40 and over. Early detection and treatment combined with lifestyle choices can help protect your sight.

Unfortunately, Glaucoma affects about 3 million people in the United States according SafeVisionTexas.org. It is one of the leading causes of vision loss, because there are no symptoms early on. Once vision is lost to glaucoma, it cannot be regained. Sadly, about half of the people with this disease do not know they have it.

Glaucoma damages the optic nerve, which transmits visual information from the retina to the brain. Typically, the disease progresses slowly, gradually destroying peripheral vision. Because people are unaware of early peripheral vision loss, a patient can lose most of it before they even know they have glaucoma.

Thats why SafeVisoinTexas.org and the American Academy of Ophthalmology recommends that everyone have acomprehensive eye exam at age 40. This exam provides ophthalmologists physicians who specialize in medical and surgical eye care an opportunity to carefully examine the eye including the optic nerve for signs of damage and other possible problems that may affect vision. Individuals at greater risk for developing glaucoma include people:

over age 40;

of African, Asian or Hispanic heritage;

who havehigh eye pressuredetected during an eye exam;

who arefarsightedornearsighted;

who have experienced eye trauma or eye injury;

whosecorneasare thin in the center;

or who have health problems such asdiabetes,migraines,high blood pressureor poor blood circulation.

Appropriate treatment for glaucoma depends on the specific type and severity of the disease. Medicatedeye dropsor laser treatments are the most common initial approach. These treatments lower eye pressure to reduce the amount offluid in the eye.

Brownwood Regional Medical Center reminds you, if you are ages 40 or above or have been experiencing eye discomfort, make that appointment now. Early detection of eye diseases may help save your eyesight.

View post:
Early detection of Glaucoma may save your sight - Brownwood Bulletin

Read More...

Lions In Sight initiative helps those who struggle to see, hear – KHON2

January 23rd, 2020 11:42 pm

Posted: Jan 22, 2020 / 08:24 PM HST / Updated: Jan 22, 2020 / 08:24 PM HST

HONOLULU (KHON2) Lions clubs worldwidewill be performing community service projects as part of theLions In Sightinitiative to raise public awareness of the vital role Lions clubs play in their communities.

As Spring cleaning gets underway, theHawaii Lionsare asking people to look through dresser drawers and closets for used eyeglasses and hearing aids and donate them to theLions Recycle For Sightprogram.

The glasses will be distributed to those in need within developing countries where eye care is often unaffordable and inaccessible.

The glasses will be cleaned, categorized by prescription and prepared for distribution by Lions, Leos, and other groups. According to the World Health Organization, the eyesight of approximately one-fourth of the worlds population can be improved through the use of a corrective lens.

Hawaii Lions collect eyeglasses year-round and the Lions members will be out in force receiving your unwanted eyewear at Walmart and other locations throughout the state.

You may also place them in specially markedLions Recycle For Sightcollection boxes.Locations are also posted on the website, visithawaiilions.organd click on Eyeglasses.

In addition to the eyeglasses,hearing aidswill be also collected, cleaned and tested for local distribution.

As part of the 11th Annual State-Wide Lions in Sight project, January 25, 2020, the Lions stationed at Kahala Mall from 10:00 a.m. 2:00 pm. will be offering free vision screening between Macys and The Walking Store.

For more information, contactKelvin Moniz(808) 652-4737 for Kauai Island, and for other islands, contact Alice Kudo456-7278 or emailpback@hawaiiantel.net

See the original post here:
Lions In Sight initiative helps those who struggle to see, hear - KHON2

Read More...

The vision thing: What do cats and dogs actually see? – C-VILLE Weekly

January 23rd, 2020 11:42 pm

Centuries of domestic breeding have resulted in cats and dogs that come in a wide variety of shapes, sizes, and colors. If you have a favorite breed, theres a good chance that you like it to some degree because of the way it looks. But what do our pets see when they look back at us?

Lets clear up the most common misconception first. Dogs do not see in black and white. They do, however, see a different color spectrum. This is because their retinasthe light-detecting membranes at the back of the eyesare built differently. Human retinas have three types of light-sensitive cells called cones, each of which is tuned to a single color: red, blue, or green. Dogs have only red and blue cones, which makes their vision similar to that of a person with red-green color blindness.

Like humans, cats have three types of cones, but they still dont see color all that well. This is because cats and dogs have another problem with color vision: Regardless of which cones they have, they dont have very many of them. Instead, their retinas are packed with a different kind of light-sensing cells, called rods, that dont detect color at all. Rods are better suited to seeing in dim light than they are to parsing the hues of rainbow. People have fewer rods than cones, so while we get to see the daytime world in bright color, we are fated to stub our toes searching for the toilet at night.

But all those rods arent the only reason why cats and dogs can see so well in the dark. Youve likely noticed your pets eyes glow bright green at night. This is courtesy of the tapetum lucidum, a reflective layer behind the retina. Any light that slips through the retina bounces off this secondary layer for another pass through the animals retina, effectively doubling its sensitivity.

Theres more to vision than color and brightness, however. Compared to people, dogs and cats have limited visual acuity. Dogs have roughly the equivalent of 20/75 vision, meaning they need to be 20 feet away from something to see it as well as a normal person could at 75 feet. And you may be surprised to hear that cats fare even worse! Those sleek and gorgeous eyes seem built for precision, but cats are close to legally blind with vision somewhere around 20/150!

Making matters worse, dogs and cats have trouble adjusting their vision to different distances. This is because their lenses cant adjust shape as readily as ours can. If youre over 40, youre familiar with what happens when your lenses start to become inflexible. It gets harder and harder to focus on anything close to your face. Welcome to life as a dog.

The short of it is that cats and dogs see better at night than we do, but those adaptations come at the cost of clarity. But poor vision doesnt slow them down any. They dont need to drive cars or read the fine print. And what they lack in eyesight, they make up with magnificently superior senses of smell and hearing. Even animals that lose their vision due to degenerative diseases do incredible job of navigating their homes, because their vision was never that great to begin with.

Dr. Mike Fietz is a small animal veterinarian at Georgetown Veterinary Hospital. He moved to Charlottesville in 2003, the same year he received his veterinary degree from Cornell University.

Continued here:
The vision thing: What do cats and dogs actually see? - C-VILLE Weekly

Read More...

Libby Clegg health: Dancing On Ice star is registered blind – what is her condition? – Express

January 23rd, 2020 11:42 pm

Libby Clegg, 29, has represented both Scotland and Great Britain at international sporting events. She won a silver medal at the 2008 Summer Paralympics and won gold at the 2016 Paralympic Games. Clearly up for any challenge, the sprinter is now competing in ITVs Dancing On Ice.

But why exactly is the star registered as blind? The sporting star has a deteriorating eye condition known as Stargardts Macular Dystrophy which gives her only slight peripheral vision in her left eye.

Libby has described her eyesight as being like looking at a pixelated computer screen or a scrunched-up firework, when speaking to The Daily mail.

She added: I have some peripheral sight - barely any - and with what little sight I do have I was able to use to use to follow the lines on the track.

Libby wasnt born blind, and started losing her eyesight at the age of 9.

But theres currently no treatment for Stargardt, and eventually, the mother-of-one will lose her entire sight.

She continued: Im at the age where my sight should be stabilising but its still deteriorating.

Things will never go black, but I dont know yet exactly what I will be able to see.

Speaking to The Radio Times about her learning process on the ice rink, Live explained: Its been a learning process.

DON'T MISS

On the track I run with a guide runner and were attached all the time, but basically its like learning a different vocabulary to communicate.

Myself and my partner Mark Hanretty use touch and verbal communication.

Im not as bad as I thought I was going to be, but its not as easy as it looks.

Its a lot harder than I thought itd be, its very technical."

Moorfields Eye Hospital, part of the NHS Foundation Trust, says Stargardt disease is a rare inherited condition affecting one in 8,000 to 10,000 people.

It explains: In Stargardts the light-sensitive layer of cells in the macular region of the eye degenerate.

The macular is the area at the back of the eye which is responsible for the fine detailed vision necessary for activities such as watching TV and reading.

Symptoms of the condition include:

Moorfields Eye Hospital says UV blocking sunglasses can offer some protection for remaining vision, but the condition is currently untreatable.

It adds: A number of novel interventions are currently under investigation, including stem cell therapies. Stem cells are a special type of cell which, when put under the right conditions, can develop into many other types of cell including those found in the macular. It is hoped that new cells derived from stem cells can be grown in a laboratory to be transplanted into the eye to replace areas of dead or non-functioning cells. Stem cells can be sourced from a number of places including blood, bone marrow, umbilical cord and fertilized egg cells.

Researchers are involved in Europes first ongoing stem cell trial for Stargardts. More research will need to be undertaken in the future to determine to what extent stem cell therapy might help improve vision for people with Stargardts.

Read more:
Libby Clegg health: Dancing On Ice star is registered blind - what is her condition? - Express

Read More...

DVLA shock: Your driving licence could be revoked for driving with this condition – Express

January 23rd, 2020 11:42 pm

Driving with poor eyesight could be a danger to other road users and data from the DVLA shows thousands lose their licence due to eye-related problems. The DVLA data, requested by car insurance prover DirectLine, found 19,644 motorists had their licence revoked between January 2017 and September 2019 for inadequate eyesight.

The data equated to over 7,000 per year or a staggering 134 per week in a devastating blow for sufferers.

The survey of 2,000 had users found 21 percent of motorists had not got their eyes tested over the last two years.

If applied to all licence holders in the UK, almost nine million have not been checked for possible poor vision.

The data revealed Brighton had the highest percentage of motorists who had not had an eye test in the last two years.

READ MORE:DVLA: Driving licences are revoked for this medical reason

A total of 33 percent said they had not had their eyes checked, closely followed by Glasgow and Leeds where 30 percent of those surveyed admitted to not having a test.

It is against the Highway Code to drive with bad eyesight as this could put you and other road users at risk of having a car crash.

Ian McIntosh, CEO of RED Driving School toldExpress.co.uk: Impaired vision may mean drivers are not able to accurately judge stopping distances or identify hazards in sufficient time.

Road signs and signals are key to ensuring road safety is adhered to those with poor eyesight can often end up reading these too late or missing them completely, putting themselves and other drivers in danger.

DON'T MISSYou could be fined 9,000 or jailed for using a dash cam[ADVICE]Drink driving myths busted in safety warning[COMMENT]Drivers breaking the law for not carrying a breathalyser here[ANALYSIS]

Impaired vision can often slow down reaction times, which are imperative for safe driving practices.

Police officers can identify motorists who may not be able to see through simple warning signs such as direction changes and late braking.

Law enforcement can then conduct a simple roadside test to see if motorists have enough vision to legally drive.

This will usually involve reading a number plate from a minimum distance of 20.5 metres or five car lengths.

Failure to pass the test could result in your licence being revoked and could potentially lead to fines.

Driving with bad eyesight could be considered careless or dangerous driving which can see penalties dramatically rise.

In severe cases, motorists could be prosecuted and sent to court where fines could be up to 5,000.

Failing to inform the DVLA of a medical condition which affects their driving ability could also land road users with a 1,000 bill.

Those with bad eyesight may need to wear glasses to ensure they are road legal and can read road signs and identify hazards correctly.

Car insurance providers may refuse to pay out for repair bills in the event of an accident caused by bad eyesight if they believe a road user failed to take precautions.

Nor wearing your glasses could be considered an at-fault claim as you did not do everything in your power to prevent the crash.

Research from GEM Motoring Assist claims poor eyesight can be linked to more than 3,000 fatal or serious accidents each year.

Data from the Royal Society for the Prevention of Accidents (RoSPA) says around 1.8 million motorists use Britains roads below the minimum legal eye standard.

Ian McIntosh adds: If you notice a change in your eyesight, whether that be struggling to read road signs or difficulty driving at night, you should visit your opticians.

Eyesight deteriorates over time and can happen at any age, so its recommended all drivers have an eye test at least every two years.

Any issues with eyesight must be addressed straight away, as not to endanger any other drivers or cause road incidents.

Read more:
DVLA shock: Your driving licence could be revoked for driving with this condition - Express

Read More...

Six out of 10 Swedish 70-year-olds could improve vision by getting new spectacles – AOP

January 23rd, 2020 11:42 pm

Researchers have found that the majority of Swedish 70-year-olds could boost their vision either by getting glasses or changing the prescription of their spectacles.

The study, which was published in Acta Ophthalmologica, reported on findings from a survey of 1200 Gothenburg residents.

The participants were asked how they perceived their eyesight and whether they thought their daily life was affected by vision problems.

Around half of participants (560) also had their central vision, peripheral vision and contrast sensitivity examined.

Scientists found that 61.5% of those surveyed could improve their sight either by getting glasses or changing the prescription of their current spectacles.

PhD student at the University of Gothenburg, Lena Havstam Johansson, shared that visual impairment can creep up on patients, making it difficult for them to notice when their eyes are getting worse.

Its a good idea to visit an optician regularly when you get older, even if you dont feel your sight is deteriorating, Ms Havstam Johansson said.

Image credit: Pixabay/Free-Photos

Read more:
Six out of 10 Swedish 70-year-olds could improve vision by getting new spectacles - AOP

Read More...

Now you see it: Test spots risk of eye disease before vision is lost – The Age

January 23rd, 2020 11:42 pm

For the around 300,000 people in Australia who have glaucoma, about half dont even know they have it, Professor MacGregor said.

By the time they go and get their eyes checked, theyve got irreversible damage, because all the treatments we have are to prevent the condition getting worse, they cant resurrect the nerve cells that have died.

Glaucoma is the catch-all term for a group of related diseases of the eye that damage the optic nerve, usually because of high pressure inside the eyeball.

It causes a gradual loss of vision, usually starting with peripheral vision, often so gradually the sufferers arent aware there is a problem until they have lost a significant portion of their sight.

It is the leading cause of irreversible blindness worldwide and is predicted to affect 76 million people by the end of this year.

Paul Neumann was 49 when he was diagnosed with glaucoma about 20 years ago, except no one bothered to tell him.

I went in for a new pair of glasses and the optometrist sent me to an ophthalmologistwho gave me some drops to take, Mr Neumann said.

That was 20 years ago.

Paul Neumann is one of the first wave of what researchers hope will be a 20,000-strong cohort to investigate glaucoma risk.

More recently I asked the opthamologist, 'Do I actually have glaucoma?' and she said, 'Yes, you do'."

Mr Neumann is now taking part in the second phase of the research.

Loading

Professor MacGregor said they wanted 20,000 people either with glaucoma or with a family history of glaucoma to take part, to help them make their test more accurate.

Theres a group of people especially who have a sort of intermediate level of risk, so we can offer them generic testing, but its not accurate enough yet to know exactly what their risk is, it might be lower or higher, he said.

If its higher, then those people need to be going to screening more regularly.

Anyone wishing to take part in the study can find a link at this website or email glaucoma_genetics@qimrberghofer.edu.au.

The research was published on Tuesday in the journal Nature Genetics.

Stuart Layt covers health, science and technology for the Brisbane Times. He was formerly the Queensland political reporter for AAP.

Read more:
Now you see it: Test spots risk of eye disease before vision is lost - The Age

Read More...

Words of wisdom, for the digital junkies – The Tribune

January 23rd, 2020 11:42 pm

All things digital rule, and most people these days are glued to a screen for several hours a day, slowly eroding away their precious eyesight. Whether at home, at the office, or even while travelling, it is almost hard to imagine life without mobile screens, computer screens and the television! For corporate professionals, both their professional and social life often involves staring intently at a screen. For these reasons, a lot of computer users today are developing digital eye strain or computer vision syndrome and experience symptoms such as eye strain, headaches, dry eyes and blurred vision, says Dr. Mahmood Husein, Head of the Ophthalmic Department, Saifee Hospital. If you spend a lot of time looking at a screen and have started to experience any of these symptoms, the first thing to do is to reduce your screen time. He further shares a few tips to take better care of your eyes:

1Place the screen at least 20 inches away from you. Ideally, the computer screen should be between 20-40 inches away. If it is too close or too distant, it may cause you to sit in an awkward position.

2Ensure that the screen is not too bright. When your screen is very bright, you are exposed to more blue light. This type of light can harm the eyes and affect vision. Instead, ensure that the room is well lit. Reduce the brightness of your screen and add a glare filter if possible. Also, reduce the colour temperature of your display in order to reduce the amount of blue light emitted by the monitor.

3Use a separate pair of computer glasses if necessary. Some people who do not need glasses for everyday use may benefit from using glasses specifically prescribed for computer use.

4Take a break and look away from your screen. Follow the 20:20:20 rule to reduce eye strain: every 20 minutes, look at an object about 20 feet away for 20 seconds. This change in focus helps relax the eye muscles.

5Keep your eyes refreshed. When you stare at a screen, you tend to blink less, which tires and dries the eyes. This, coupled with the air-conditioning, may result in the eyes becoming very dry. To avoid this, take a break every couple of hours to splash some cold water on the eyes. Remember to blink more often to keep the eyes lubricated. Cooling drops also help. If you still experience any vision troubles, visit an ophthalmologist at the earliest. IANS

Link:
Words of wisdom, for the digital junkies - The Tribune

Read More...

Gene Therapy Protects Eyesight in Models of Multiple Sclerosis – Technology Networks

January 23rd, 2020 11:42 pm

New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms. The paper, published in Immunity, also shows how gene therapy may be used to preserve neural circuits and protect against vision loss in the disease.

These findings suggest a path for developing therapies that may protect synapses from the damaging effects of MS and could be broadly applicable to other neurodegenerative disorders, according to Dr. Schafer, assistant professor of neurobiology, and Sebastian Werneburg, PhD, a postdoctoral fellow in the Schafer lab.

"Most MS research and FDA-approved treatments focus on demyelination and axon death," said Schafer. "Far less is known about what happens to the synaptic connections between neurons, which has proven to be a key aspect of neurodegeneration likely leading to cognitive decline in other diseases such as Alzheimer's disease."

Multiple sclerosis is a neurological disease of the central nervous system affecting more than 2 million people worldwide. The disease involves an abnormal response of the body's peripheral immune system against the brain, spinal cord and optic nerves, which damages the fatty substance surrounding nerve fibers called myelin. Recurrent episodes of inflammation result in demyelination. As the myelin is stripped away, the nerve fibers are exposed to inflammatory attacks from the immune system and the transmission of nerve signals within the central nervous system are altered or stopped completely. A small subset of MS patients experience chronic progressive neurodegenerative symptoms accompanied by significant synaptic loss and central nervous system atrophy. This version of the disease is called progressive MS.

FDA-approved medications for treating MS have been developed to limit and reduce the number of relapses, which delay progression of the disease and minimize demyelination, but there is no cure for the disease and patients are still left with disability. Current therapies work to inhibit peripheral immune attack of the central nervous system and inflammatory demyelination, but the neurodegenerative aspects of the disease have proven harder to decelerate, particularly for patients with progressive MS.

Vison loss is one of the most common symptoms of MS and is often one of the first that patients notice. Problems with vision result from damage to the optic nerve that connects the eye to the brain or from lack of coordination in the eye muscle.

"The retinogeniculate system, which comprises neurons that extend their axons via the optic nerve to the thalamus in the brain, is an ideal model for investigating MS because it's easy to access for therapeutic intervention, subtle changes can be readily detected and the visional pathway is affected in almost half of all patients with the disease," said Dr. Werneburg.

Profound synaptic loss was observed in animal models as microglia engulfed and eliminated presynaptic connections. Microglia are the immune cells of the central nervous system and are emerging as key players in regulating neural circuit structure in health and disease. One of the vast number of functions microglia perform in the brain is similar to the role macrophages perform in the immune system: clearing cellular decay and dead neurons from tissue.

"We found the protein C3 in abundance at synapses," said Werneburg.

C3 is not normally found in adult brain tissue. C3 protein usually only shows up in neural tissue during the developmental stages of the brain when synapses are being pruned. Synaptic pruning eliminates weak or unused synapsis as the brain matures to help efficiency and conserve energy.

In the case of demyelinating disease, it is not known why C3 is being produced and activated. This complement protein binds to synapses, sending the signal to microglia that the otherwise healthy-seeming synapse should be eliminated. This leads microglia to attack synapses.

Schafer, in collaboration with Guangping Gao, PhD, the Penelope Booth Rockwell Professor in Biomedical Research, professor of microbiology & physiological systems, director of the UMMS Horae Gene Therapy Center and Viral Vector Core, and co-director of the Li Weibo Institute of Rare Disease, used a gene therapy approach and adeno-associated virus to deliver Crry, an inhibitor of C3, specifically to synapses in the visual system while leaving the rest of the brain untouched, to see if synapses could be spared and vision preserved. Crry is a natural inhibitor of complement proteins such as C3. These regulators help protect cells or tissue from unwanted attack by the immune system.

After injection of the AAV into the circuit, Crry localized to synapses and successfully preserved them by binding to C3 so microglia couldn't damage them.

"As a result of this inhibition, we saw improved visional function in mice," said Werneburg.

Schafer said the protective effects of the AAV-delivered inhibitor were specific to the visual circuit. "It's possible that therapies targeting different circuits of the brain can be used to protect against synaptic damage in other neurodegenerative diseases such as Alzheimer's."

The next step for Schafer and colleagues will be to determine how the C3 protein is being activated and produced during MS and other neurodegenerative diseases.

Reference: Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., Popko, B., Reich, D. S., & Schafer, D. P. (2020). Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease. Immunity, 52(1), 167-182.e7. https://doi.org/10.1016/j.immuni.2019.12.004

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Link:
Gene Therapy Protects Eyesight in Models of Multiple Sclerosis - Technology Networks

Read More...

Page 735«..1020..734735736737..740750..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick